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The developmentofthe bacterial artiﬁcialchromosome(BAC)system wasdriven inpart by the humangenomeproject inorder to
constructgenomicDNA librariesandphysical mapsforgenomicsequencing.The availabilityofBACcloneshasbecome avaluable
tool for identifying cancer genes. We report here our experience in identifying genes located at breakpoints of chromosomal
rearrangements and in deﬁning the size and boundaries of deletions in hematological diseases. The methodology used in our
laboratory consistsof a three-step approach using conventionalcytogenetics followed by FISH with commercial probes, then BAC
clones. One limitation to the BAC system is that it can only accommodate inserts of up to 300kb. As a consequence, analyzing the
extent of deletions requires a large amount of material. Array comparative genomic hybridization (array-CGH) using a BAC/PAC
system can be an alternative. However, this technique has limitations also, and it cannot be used to identify candidate genes at
breakpoints of chromosomalrearrangements such as translocations,insertions, and inversions.
1.Introduction
Since chromosome banding techniques have been applied
to the analysis of chromosomal aberrations in leukemia
and cancer, several hundreds of recurring chromoso-
mal breakpoints have been identiﬁed. They also allowed
the recognition of regions of nonrandom copy number
changessuchasdeletions.Thesechromosomal abnormalities
point to the location of genes involved in the genesis
and progression of leukemia and cancer (http://www.ncbi
.nlm.nih.gov/sites/entrez?db=cancerchromosomes).
The developmentof molecular cytogenetic methodology
(ﬂuorescent in situ hybridization—FISH) improved the
level of resolution and increased the number of recurring
chromosomal abnormalities, notably by recognizing cryptic
translocations and deletions. However, thelevelofresolution
in cancer cytogenetics is not ﬁne enough to be used for
positional cloning of genes at chromosomal breakpoints or
those tumor suppressor genes mapping to regions subjected
to deletion.
Therefore, the availability of large-insert genomic
librairies such as bacterial artiﬁcial chromosomes (BACs) is
a valuable tool for identifying cancer genes. Indeed, it is now
widely used in sequencing eﬀorts and in studies of genomics
and functional genomics [1–3].
We illustrate here by several examples our experi-
ence at the University Cytogenetics Laboratory in Brest
(France) using BAC clones to identify genes at chromo-
somal breakpoints and deﬁne commonly deleted regions
in myelodysplastic syndromes, myeloproliferative neoplasms
and leukemia.2 Journal of Biomedicine and Biotechnology
2.Methodology
Athree-stepmethodologyconsisting in conventionalcytoge-
netics followed by FISH with commercial probes, then BAC
clones is currently used in the laboratory.
2.1. Conventional Cytogenetics. Cytogenetic analysis is per-
formed on bone marrow cells of patients at the time of
the diagnosis and/or relapse(s). Bone marrow cultures are
synchronized for 17 hours by ﬂuorodeoxyuridin (FudR
10−7 M), before being released by thymidine (10−5 M) for
6 hours. They are then exposed to colcemid and standard
harvested. The chromosomes are R-banded and the kary-
otypes described according to the International System for
Cytogenetic Nomenclature (ISCN 2005) [4].
2.2. FISH Analyses with Commercially Available Probes.
Should one or several chromosomal abnormalities be iden-
tiﬁed by conventional cytogenetics, FISH studies using
commercially available probes are performed on the same
ﬁxed material, stored in ﬁxative at −20◦C until utilization,
as the conventional cytogenetic analyses. These probes
include whole chromosome paints (WCP), chromosome
enumeration probes (CEP), locus-speciﬁc identiﬁers (LSI)
and subtelomeric speciﬁc probes. In case of noninforma-
tiveness of the R-banded karyotypes, 24-color FISH using
MetaSystems’24Xcyte probe kit (MetaSystems, Altlussheim,
Germany)isappliedtocharacterize thechromosomal abnor-
malities. All probes are used according to the suggested
manufacturers’ protocols.
Furthermore, cryptic rearrangements (translocations,
deletions, insertions) of ubiquitous genes such as the MLL
and RUNX1 (AML1) genes are searched for in speciﬁc
hematological disorders.
2.3. FISH Analyses with BAC Clones. We identify the BAC
clones of interest through the human genome browser
database of the genome bioinformatics group at the univer-
sity of California at Santa Cruz (http://genome.ucsc.edu/)
and ensembl genome data resources of the Sanger Insti-
tute genome database (http://www.ensembl.org/). They are
then ordered by Internet on the site of the Children’s
Hospital Oakland Research Institute in Oakland, California
(http://bacpac.chori.org/).
When received, bacterial cultures are prepared from a
single colony picked from a selective plate in the presence
of chloramphenicol. Plasmids are obtained from bacte-
rial cultures grown in the presence of chloramphenicol
(10mg/L). After having lysed bacteria using SDS1%/NaOH
0.2N,DNAispuriﬁed fromRNA,proteinsand othercellular
contaminants. Probes are then labelled by nick translation
in Spectrum Orange (Nick Translation Kit, Abbott, Rungis,
France) or in FITC (Prime-it Fluor Fluorescence Labeling
Kit, Stratagene, Amsterdam, Netherlands). All BAC clones
are applied to normal lymphocyte metaphases to conﬁrm
their chromosomal location [5].
Because of the limited resolution and the usual poor
morphology ofthechromosome preparation in haematolog-
ical malignancies, we use, in ﬁrst intention, an appropriate
setofBACcloneslocatedevery1.5to2Mbaroundthebreak-
point(s). Contig BACs are then used to precisely determine
the breakpoint(s). Several FISH assays can be carried out
consecutivelyonthesamemetaphasesafterde-hybridization,
following the protocol described by Wang et al. [6].
After hybridization, the slides are counterstained with
4-6-diamino-2-phenyl-indole-dihydrochloride (DAPI). The
preparations are examined using a Zeiss Axio Plan Micro-
scope (Zeiss, Le Pecq, France). Images acquisition is per-
formedusingaCCDcameraandanalyzedusingtheISISpro-
gram (In Situ Imaging System) (MetaSystems, Altlussheim,
Germany).
3.IdentiﬁcationofGenesat
ChromosomalBreakpoints
We use BAC clones to precisely locate the breakpoints of
recurrent chromosomal abnormalities. This is illustrated by
the following three examples.
3.1. Identiﬁcation of Genes Involved in Newly Recognized
Recurrent Translocations. Two patients, a 13-year-old boy
and a 40-year-old woman, were ﬁrst seen because of a
history of asthenia. At admission, both presented signs of
disseminated intravascular coagulation. A diagnosis of acute
myeloid leukemia, M1 subtype in the FAB classiﬁcation,
without maturation in the WHO classiﬁcation was made in
both patients [7].
A chromosomal translocation, t(10;17)(p15;q21), was
found in both patients. Initial FISH studies using the LSI
PML/RARAdual-colortranslocation probe (Abbott,Rungis,
France) showed the RARA signal to remain on the derivative
chromosome 17, providing evidence that the translocation
breakpoint was telomeric to the RARA locus.
Twelveand14BACcloneswereselectedonchromosomes
10 and 17, respectively (Figure 1). The breakpoint occurred
in RP11-10D13 on chromosome 10 and in RP11-379D19
on chromosome 17 in both patients. Five and 6 BAC clones
spanning both breakpoint sites on chromosomes 10 and
17 were hybridized to conﬁrm their location. Clone RP11-
10D13 is located in band 10p15.3 and spans the ZMYND11
andDIP2Cgenes.TheZMYND11genecodesacorepressorof
transcription through recruitment of N-CoR and the DIP2C
gene a member of the disco-interacting protein homolog 2
family that shares strong similarity with aDrosophilaprotein
which interacts with the transcription factor disco. Clone
RP11-379D19 is located in band 17q21.33 and contains
the NME1 gene, which might regulate diﬀerent stages of
the diﬀerentiation process during hematopoiesis, depending
on the speciﬁc cellular lineage. Work is still underway to
determine the partner gene on chromosome 10 and whether
this putative fusion gene is transcribed.
3.2. Identiﬁcation of New Gene Partners Fusing with Already
Known Genes: The ABL1 Example. This 11-year old boyJournal of Biomedicine and Biotechnology 3
(a) (b)
Figure 1: Identiﬁcation of breakpoints involved in a newly recognized recurrent translocation, t(10;17)(p15;q21). (a) Representation of
the breakpoint (dotted line) on the short arm of chromosome 10 for both patients by FISH with BACs. Applied BAC clones are bordered;
candidate genes are surrounded. (b) Representation ofthe breakpoint (dotted lines) onthe longarm of chromosome17 for both patients by
FISH with BACs. Applied BAC clones are bordered; candidate genes are surrounded.
was ﬁrst seen for consolidation chemotherapy of a pre-
B acute lymphoblastic leukemia that had been diagnosed
elsewhere. Subsequently,he developed relapse, at which time
karyotyping of bone marrow cells showed a t(1;9)(q24;q34).
Using LSIbcr/abldual extra-signal (ES)colorprobe(Abbott,
Rungis, France) in FISH experiments, three red signals
were seen, one on the normal chromosome 9, one on the
der(9) and another on the der(1), signing the t(1;9) with
involvement of the ABL1 gene.
To map the breakpoints of the t(1;9)(q24;q34),FISH was
performed with appropriate sets of BAC clones. One BAC
in band 9q34, RP11-83J21 containing the ABL1 gene and
16 on chromosome arm 1q were ordered. The probe from
chromosome 9 was labelled by nick translation in Spectrum
Orange and those from chromosome 1 in Spectrum Green.
Split signals were observed for RP11-83J21 and RP11-
232M22. Cohybridization with these two probes show two
yellow fusion signals (Figure 2)[ 8]. Clone RP11-232M22 is
located in band 1q24.2 and contains the RCSD1 gene, which
codes a protein kinase substrate, CapZIP (CapZ-interacting
protein). This may inﬂuence cytoskeleton regulation and/or
cell migration.
RT-PCR conﬁrmed that the ABL1-RCSD1 fusion gene
was transcribed. Sequencing revealed that the PCR product
consisted of the ﬁrst 3 exons of the ABL1 gene fused to
RCSD1 starting from exon 4.
3.3. Identiﬁcation of New Gene Partners Fusing with Already
Known Genes: The MLL Example. Most of the MLL gene
breakpoints involved in fusion genes occur in a region called
breakpointclusterregion(BCR).Thisledtothedevelopment
of a long-distance inverse-polymerase chain reaction (LDI-
PCR) used to identify the MLL fusion partner genes involved
in chromosomal rearrangements [9].
A 5 month-old-boy was ﬁrst seen at the pediatric
emergency room for left hemiplegia and right hemi-
anopsia. A diagnosis of acute myelomonoblastic leukemia
Figure 2: Identiﬁcation of a new partner gene, RCSD1,f u s e d
to ABL1 in acute lymphoblastic leukemia. Dual-color FISH using
RP11-83J21 (labeled in spectrum orange) and RP11-232M22
(labeled in spectrum green) showing two fusion genes.
(FAB classiﬁcation type 4) with severe diﬀuse intravas-
cular coagulopathy was made [10]. Cytogenetic analysis
performed on bone marrow cells at diagnosis showed a
46,XY,ins(11;X)(q23;q28q12). FISH analysis using the LSI
MLL dual color probe (Abbott, Rungis, France) conﬁrmed
the disruption of the MLL g e n ea n ds h o w e dt h ei n s e r t i o no f
chromosomal material between the green(5  regionof MLL)
and red (3  region of MLL)s i g n a l s( Figure 3(a)).
Sequence analysis of the PCR amplimers obtained by
LDI-PCR (Figure 3(b)) revealed that the 5  region of MLL
(break in intron 10) was fused in-frame with the 3 
region of Filamin a (FLNA) (break in intron 19), a gene
located in chromosomal band Xq24 [11]. The chromosomal
rearrangement was investigated in more detail using BAC
clones, RP11-91A14 and RP11-770J1 covering MLL and
CTD-2238E23, CTD-2565C16 and CTD-2511C7 spanning
FLNA. A fusion signal involving MLL and FLNA was4 Journal of Biomedicine and Biotechnology
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Figure 3: Identiﬁcation of a new partner gene, FLNA,f u s e dt oMLL in acute myelomonoblastic leukemia. (a) FISH with dual-color MLL
probe showing the insertion of chromosomalmaterial within the disrupted signal of the MLL gene on the der(11). The yellow signal of the
normal MLL is seen on the normal chromosome 11. (b) LDI-PCR of analyzed patient. The wild-type band in lane 2 does not appear. M:
λ-Clal marker, 1: der(11), 2: der(reciprocal partner gene), ∗: derivative band. (c) FISH with BAC clones CTD-2238E23 (FLNA) (labeled in
Spectrum Orange) and RP11-91A14 (MLL) (labeled in FITC) showingtwo green signals,two red signals and one yellow signal.
observed (Figure 3(c)). RT-PCR conﬁrmed that this MLL-
FLNA fusion gene was transcribed.
4.ExtentofDeletions
Chromosomal deletion is commonly observed in hemato-
logical diseases. Deletions of some chromosome arms, such
as 5q, 7q and 20q, are recurrently identiﬁed in myelodys-
plastic syndromes, myeloproliferative neoplasms and acute
myeloblastic leukemia.
However, the degree of elongation of the chromosomes
doesnot allow the boundaries of the deletions to be precisely
deﬁned between patients, or even between diﬀerent clones
in a same patient. Fluorescent in situ hybridization with BAC
clonescanthenbe usedto determinethe size and boundaries
ofdeletions.Thisisillustratedbythefollowingtwoexamples.
4.1. Delineation of 5q Deletions in Several Clones of a
Patient with Myelodysplastic Syndrome. This 74-year-old
male patient was ﬁrst seen because of a history of anemia.
Microscopic examination of the bone marrow aspirate
revealed morphologic abnormalities of the megakaryocytic
lineage, especially monolobulated nuclei resembling those of
the 5q-syndrome, associated with other features consistent
with dysgranulopoiesis and dyserythropoiesis.Journal of Biomedicine and Biotechnology 5
Table 1: FISH results with BAC clones located on the long arm of chromosome 5. Delineation of deleted (
￿)a n dr e t a i n e d(
￿)r e g i o n so f
chromosome5 in clones A, B, and C.
Cytogenetic band BAC clone Position clone A clone B clone C
del(5) der(5) der(5)
q11.2 RP11-300G6 51,53–51,71
￿
￿
￿
q11.2 RP11-343F4 52,93–53,12
￿
￿
￿
q14.3 RP11-467D4 87,60–87,78
￿
￿
￿
q14.3 RP11-44N15 87,80–87,99
￿
￿
￿
q22.3 RP11-68A11 114,44–114,61
￿
￿
￿
q22.3 RP11-930P16 115,07–115,26
￿
￿
￿
q31.2 RP11-103I17 135,37–135,54
￿
￿
￿
q31.2 RP11-27C15 136,78–136,96
￿
￿
￿
q33.1 RP11-1152G8 151,04–151,17
￿
￿
￿
q33.1 RP11-602K10 151,16–151,33
￿
￿
￿
q33.3 RP11-152N9 156,68–156,88
￿
￿
￿
q33.3 RP11-631N12 157,00–157,17
￿
￿
￿
Table 2: Size and boundaries of commonly deleted regions in del(20q) and ider(20q) patients.
del(20q) MDS del(20q) MPN del(20q) MDS/MPN ider(20q) MDS All patients
Proximal breakpoint RP11-1039F8 RP11-467A7 RP11-298O1 RP11-60H7 RP11-1039F8
Distal breakpoint RP11-293N18 RP11-1013P13 RP11-171L8 RP11-124P7 RP11-171L8
Size (Mb) 10.4 7.4 7.9 17.9 6.6
MDS: myelodysplasticsyndrome; MPN: myeloproliferative neoplasm.
Clone A Clone B Clone C
Figure 4: RHG banding of chromosomes 5 in a patient with three
diﬀerent clones.
Chromosome banding analysis showed three clones
(Figure 4): 46,XY,del(1)(p34),del(5)(q14q23) [2] (clone A)/
46,XY, del(1)(p34),del(5)(q14q34) [10] (clone B)/46,sl2,
inv(5)(q?11q?34) [7] (clone C). In order to precisely deter-
mine the breakpoints (proximal and distal), leading to the
deﬁnition of the deleted region in this patient, metaphase
FISH mapping was performed with an appropriate set of 20
BAC clones.
The complex nature of deleted chromosomes 5 in
the three clones was revealed by sequential hybridization
(Table 1). Clone A exhibited a deletion of some 27Mb
between bands 5q14.3 and 5q22.3. The same deletion was
observed in clones B and C but a more distal deletion of
about 20Mb between bands 5q31.2 and 5q33.3 was also
found in both clones.
4.2. Dissection of Chromosome 20 in Hematological Disorders.
Deletion of the long arm of chromosome 20 [del(20q)] is
a recurrent abnormality observed in myelodysplastic syn-
dromes and in Philadelphia-chromosome-negative myelo-
proliferative neoplasms [5]. Isochromosome of the long
arm of chromosome 20 with loss of interstitial material
[ider(20q)]is a variant of deletion of chromosome 20q and a
rare abnormality in myelodysplastic syndrome [12].
A deletion of the long arm of chromosome 20 was
detected by RHG banding in 38 patients, including 22
withmyelodysplastic disorders(MDS),12withPhiladelphia-
chromosome-negative myeloproliferative neoplasms (MPN)
and 4 with MDS/MPN. An ider(20q) was identiﬁed in 7
patientswithMDS.Sixty-sixBACclonesdistributedbetween
bands20q11.1and20q13.33wereusedtodeterminenotonly
both proximal and distal breakpoints of the del(20q) and
ider(20q) but also the size of the commonly deleted region
(CDR) in each subpopulation of patients (Table 2).
The location of the proximal and distal breakpoints was
highly variable among patients with del(20q) or ider(20q).
Although no recurrent breakpoint was found, the distal6 Journal of Biomedicine and Biotechnology
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Figure 5:Ideogram ofthe longarm ofchromosome20.Delineationof commonlydeleted regions (CDR). MDS:myelodysplastic syndrome;
MPN: myeloproliferative neoplasm.
breakpoint occurred between RP11-112L6 and RP11-80K6
in a 2.6 megabases interval in 16 of the 38 patients with
del(20q). The proximal breakpoint was located in band
20q11.21 for all patients with ider(20q), between RP11-
392M18 and RP11-60H7, in a 1 megabase interval. A
recurrent breakpoint located between RP11-392M18 and
RP11-380E19 was even observed in 57% of the patients with
ider(20q) [5, 12].
Although the shared commonly deleted region encom-
passed 6.6Mb, being located between bands q12 and q13.1,
diﬀerences in size and location were observed between the
three groups with del(20q) whereas the size of CDR in
patients with ider(20q) was much larger (17.9 megabases)
(Figure 5)[ 5, 12].
5.Conclusion
The development of the Bacterial Artiﬁcial Chromosome
system was driven in part by the Human Genome Project
in order to construct genomic DNA libraries and physical
maps for genomic sequencing [13]. BACs have now become
essential tools in cancer research. One limitation to the sys-
tem is that it can only accommodate inserts of up to 300kb.
Asa consequence,analyzing the extentofdeletionswith BAC
clones requires a large amount of material. Array compara-
tive genomic hybridization (array-CGH) using a BAC/PAC
system can be an alternative. However, this technique has
also limitations and it cannot be used to identify candidate
genes at breakpoints of chromosomal rearrangements such
as translocations, insertions and inversions.
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